Clinical implications of platelet - Vessel interaction

Journal of Cardiovascular Translational Research

Volumn 6, Issue 3, 2013, Pages 310-315

  Mangiacapra, Fabio ^a   Barbato, Emanuele ^a  

^a CARDIOVASCULAR CENTER   (Belgium)

Author keywords

Clopidogrel; Endothelium; Percutaneous coronary intervention; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; CYCLOOXYGENASE 1; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; PADGEM PROTEIN; PRASUGREL; THROMBOXANE; TICAGRELOR; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULATION; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; BRAIN ATHEROSCLEROSIS; CELL INTERACTION; CELL STIMULATION; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY STENT; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HEART MUSCLE REVASCULARIZATION; HEMOSTASIS; HUMAN; INFLAMMATORY CELL; ISCHEMIA; LEUKOCYTE AGGREGATION; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MUSCLE NECROSIS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INTERACTION; RECURRENT DISEASE; STABLE ANGINA PECTORIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; THROMBOSIS PREVENTION; UNSPECIFIED SIDE EFFECT; VASODILATATION;

ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; BLOOD VESSELS; ENDOTHELIAL CELLS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; THROMBOSIS;

EID: 84877752900     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-012-9441-0     Document Type: Article

References (50)

1. Davi, G., & Patrono, C. (2007). Platelet activation and atherothrombosis. The New England Journal of Medicine, 357, 2482-94.
2. Ombrello, C., Block, R. C., & Morrell, C. N. (2010). Our expanding view of platelet functions and its clinical implications. Journal of Cardiovascular Translational Research, 3, 538-46.
3. Gawaz, M., Neumann, F. J., Dickfeld, T., Reininger, A., Adelsberger, H., Gebhardt, A., et al. (1997). Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation, 96, 1809-18.
4. Bombeli, T., Schwartz, B. R., & Harlan, J. M. (1998). Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha. The Journal of Experimental Medicine, 187, 329-39.
5. Gawaz, M., Langer, H., & May, A. E. (2005). Platelets in inflammation and atherogenesis. The Journal of Clinical Investigation, 115, 3378-84.
6. May, A. E., Seizer, P., & Gawaz, M. (2008). Platelets: inflammatory firebugs of vascular walls. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, s5-10.
7. Henn, V., Slupsky, J. R., Grafe, M., Anagnostopoulos, I., Forster, R., Muller-Berghaus, G., et al. (1998). CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 391, 591-94.
8. May, A. E., Kalsch, T., Massberg, S., Herouy, Y., Schmidt, R., & Gawaz, M. (2002). Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation, 106, 2111-17.
9. Mayadas, T. N., Johnson, R. C., Rayburn, H., Hynes, R. O., & Wagner, D. D. (1993). Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell, 74, 541-54.
10. Subramaniam, M., Saffaripour, S., Watson, S. R., Mayadas, T. N., Hynes, R. O., & Wagner, D. D. (1995). Reduced recruitment of inflammatory cells in a contact hypersensitivity response in P-selectin-deficient mice. The Journal of Experimental Medicine, 181, 2277-82.
11. Husain, S., Andrews, N. P., Mulcahy, D., Panza, J. A., & Quyyumi, A. A. (1998). Aspirin improves endothelial dysfunction in atherosclerosis. Circulation, 97, 716-20.
12. Heitzer, T., Ollmann, I., Koke, K., Meinertz, T., & Munzel, T. (2003). Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease. Circulation, 108, 536-41.
13. Jakubowski, A., Chlopicki, S., Olszanecki, R., Jawien, J., Lomnicka, M., Dupin, J. P., et al. (2005). Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 72, 139-45.
14. Ziemianin, B., Olszanecki, R., Uracz, W., Marcinkiewicz, E., & Gryglewski, R. J. (1999). Thienopyridines: effects on cultured endothelial cells. Journal of Physiology and Pharmacology, 50, 597-604.
15. Heitzer, T., Rudolph, V., Schwedhelm, E., Karstens, M., Sydow, K., Ortak, M., et al. (2006). Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 1648-52.
16. Warnholtz, A., Ostad, M. A., Velich, N., Trautmann, C., Schinzel, R., Walter, U., et al. (2008). A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. Atherosclerosis, 196, 689-95.
17. Muller, O., Hamilos, M., Bartunek, J., Ulrichts, H., Mangiacapra, F., Holz, J. B., et al. (2010). Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. The American Journal of Cardiology, 105, 333-38.
18. Hamilos, M., Muller, O., Ntalianis, A., Trana, C., Bartunek, J., Sarno, G., et al. (2011). Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. Journal of Thrombosis and Thrombolysis, 32, 64-71.
19. Patti, G., Grieco, D., Dicuonzo, G., Pasceri, V., Nusca, A., & Di Sciascio, G. (2011). High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. Journal of the American College of Cardiology, 57, 771-78.
20. Barbato, E., Bartunek, J., Wyffels, E., Wijns, W., Heyndrickx, G. R., & De Bruyne, B. (2003). Effects of intravenous dobutamine on coronary vasomotion in humans. Journal of the American College of Cardiology, 42, 1596-601.
21. Barbato, E., Piscione, F., Bartunek, J., Galasso, G., Cirillo, P., De Luca, G., et al. (2005). Role of beta2 adrenergic receptors in human atherosclerotic coronary arteries. Circulation, 111, 288-94.
22. Methia, N., Andre, P., Denis, C. V., Economopoulos, M., & Wagner, D. D. (2001). Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood, 98, 1424-28.
23. Egan, K. M., Wang, M., Fries, S., Lucitt, M. B., Zukas, A. M., Pure, E., et al. (2005). Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation, 111, 334-42.
24. Pratico, D., Cyrus, T., Li, H., & FitzGerald, G. A. (2000). Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood, 96, 3823-26.
25. Dixon, D. A., Tolley, N. D., Bemis-Standoli, K., Martinez, M. L., Weyrich, A. S., Morrow, J. D., et al. (2006). Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. The Journal of Clinical Investigation, 116, 2727-38.
26. Barbato, E., Rubattu, S., Bartunek, J., Berni, A., Sarno, G., Vanderheyden, M., et al. (2009). Human coronary atherosclerosis modulates cardiac natriuretic peptide release. Atherosclerosis, 206, 258-64.
27. Jayachandran, M., Litwiller, R. D., Lahr, B. D., Bailey, K. R., Owen, W. G., Mulvagh, S. L., et al. (2011). Alterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk. Journal of Cardiovascular Translational Research, 4, 811-22.
28. Koyama, H., Maeno, T., Fukumoto, S., Shoji, T., Yamane, T., Yokoyama, H., et al. (2003). Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation, 108, 524-29.
29. Fateh-Moghadam, S., Li, Z., Ersel, S., Reuter, T., Htun, P., Plockinger, U., et al. (2005). Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 1299-303.
30. Furman, M. I., Benoit, S. E., Barnard, M. R., Valeri, C. R., Borbone, M. L., Becker, R. C., et al. (1998). Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. Journal of the American College of Cardiology, 31, 352-58.
31. Furman, M. I., Barnard, M. R., Krueger, L. A., Fox, M. L., Shilale, E. A., Lessard, D. M., et al. (2001). Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. Journal of the American College of Cardiology, 38, 1002-06.
32. Keating, F. K., Whitaker, D. A., Kabbani, S. S., Ricci, M. A., Sobel, B. E., & Schneider, D. J. (2004). Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. The American Journal of Cardiology, 94, 725-28.
33. Mangiacapra, F., De Bruyne, B., Muller, O., Trana, C., Ntalianis, A., Bartunek, J., et al. (2010). High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC. Cardiovascular Interventions, 3, 35-40.
34. Tcheng, J. E., Lim, I. H., Srinivasan, S., Jozic, J., Gibson, C. M., O'Shea, J. C., et al. (2009). Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial. Circulation. Cardiovascular Interventions, 2, 43-51.
35. Wang, T. H., Bhatt, D. L., Fox, K. A., Steinhubl, S. R., Brennan, D. M., Hacke, W., et al. (2007). An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal, 28, 2200-07.
36. Mangiacapra, F., Barbato, E., Patti, G., Gatto, L., Vizzi, V., Ricottini, E., et al. (2010). Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. JACC. Cardiovascular Interventions, 3, 318-23.
37. Mangiacapra, F., Patti, G., Peace, A., Gatto, L., Vizzi, V., Ricottini, E., et al. (2010). Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. The American Journal of Cardiology, 106, 619-23.
38. Breet, N. J., van Werkum, J. W., Bouman, H. J., Kelder, J. C., Ruven, H. J., Bal, E. T., et al. (2010). Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA: The Journal of the American Medical Association, 303, 754-62.
39. Mangiacapra, F., Patti, G., Barbato, E., Peace, A. J., Ricottini, E., Vizzi, V., et al. (2012). A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (antiplatelet therapy for reduction of MYocardial damage during angioplasty-platelet reactivity for outcome validation effort) study. JACC. Cardiovascular Interventions, 5, 281-89.
40. Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., et al. (2001). Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. The Lancet, 358, 527-33.
41. Steinhubl, S. R., Berger, P. B., Mann, J. T., Fry, E. T., DeLago, A., Wilmer, C., et al. (2002). Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA: The Journal of the American Medical Association, 288, 2411-20.
42. Saito, Y., Wada, H., Yamamuro, M., Inoue, A., Shimura, M., Hiyoyama, K., et al. (1999). Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. American Journal of Hematology, 61, 238-42.
43. Serrano, C. V. J., Ramires, J. A., Venturinelli, M., Arie, S., D'Amico, E., Zweier, J. L., et al. (1997). Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. Journal of the American College of Cardiology, 29, 1276-83.
44. Scharf, R. E., Tomer, A., Marzec, U. M., Teirstein, P. S., Ruggeri, Z. M., & Harker, L. A. (1992). Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscler Thromb, 12, 1475-87.
45. Gurbel, P. A., Samara, W. M., & Bliden, K. P. (2004). Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets, 15, 95-99.
46. Matetzky, S., Shenkman, B., Guetta, V., Shechter, M., Beinart, R., Goldenberg, I., et al. (2004). Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation, 109, 3171-75.
47. Siller-Matula, J. M., Haberl, K., Prillinger, K., Panzer, S., Lang, I., & Jilma, B. (2009). The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. Thrombosis Research, 123, 874-80.
48. Mangiacapra, F., Bartunek, J., Bijnens, N., Peace, A. J., Dierickx, K., Bailleul, E., et al. (2012). Peri-procedural variations of platelet reactivity during elective percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 10(12), 2452-61.
49. Price, M. J., Berger, P. B., Teirstein, P. S., Tanguay, J. F., Angiolillo, D. J., Spriggs, D., et al. (2011). Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA: The Journal of the American Medical Association, 305, 1097-105.
50. Collet, J. P., Cuisset, T., Range, G., et al. (2012). Bedside monitoring to adjust antiplatelet therapy for coronary stenting. The New England Journal of Medicine, 367(22), 2100-9.